Agilent Technologies, Inc. (A) Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. boosted its position in Agilent Technologies, Inc. (NYSE:A) by 45.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,145,610 shares of the medical research company’s stock after buying an additional 3,779,099 shares during the period. JPMorgan Chase & Co. owned 3.78% of Agilent Technologies worth $720,358,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in A. Skandinaviska Enskilda Banken AB publ increased its stake in shares of Agilent Technologies by 5.7% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 64,834 shares of the medical research company’s stock valued at $3,428,000 after buying an additional 3,489 shares during the period. British Columbia Investment Management Corp increased its stake in shares of Agilent Technologies by 96.7% in the first quarter. British Columbia Investment Management Corp now owns 357,983 shares of the medical research company’s stock valued at $18,927,000 after buying an additional 175,992 shares during the period. Jennison Associates LLC bought a new stake in shares of Agilent Technologies during the second quarter valued at about $212,000. Henderson Group PLC increased its stake in shares of Agilent Technologies by 2.2% in the first quarter. Henderson Group PLC now owns 37,408 shares of the medical research company’s stock valued at $1,978,000 after buying an additional 800 shares during the period. Finally, Xact Kapitalforvaltning AB increased its stake in shares of Agilent Technologies by 11.3% in the first quarter. Xact Kapitalforvaltning AB now owns 26,199 shares of the medical research company’s stock valued at $1,385,000 after buying an additional 2,657 shares during the period.
Shares of Agilent Technologies, Inc. (NYSE A) traded down 0.53% during trading on Friday, hitting $64.38. The company had a trading volume of 1,224,667 shares. Agilent Technologies, Inc. has a 12-month low of $42.92 and a 12-month high of $65.18. The firm has a 50 day moving average of $61.25 and a 200 day moving average of $57.11. The stock has a market cap of $20.73 billion, a PE ratio of 33.20 and a beta of 1.30.
Agilent Technologies (NYSE:A) last released its earnings results on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.07. The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Agilent Technologies had a return on equity of 16.95% and a net margin of 14.36%. The company’s revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.49 EPS. On average, analysts forecast that Agilent Technologies, Inc. will post $2.32 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://www.watchlistnews.com/agilent-technologies-inc-a-shares-bought-by-jpmorgan-chase-co/1538197.html.
Several analysts recently issued reports on A shares. Morgan Stanley reissued an “overweight” rating on shares of Agilent Technologies in a report on Monday, July 10th. Jefferies Group LLC raised their price target on Agilent Technologies from $59.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, May 23rd. Deutsche Bank AG reissued a “buy” rating and issued a $66.00 price target on shares of Agilent Technologies in a report on Thursday, June 22nd. BTIG Research lifted their target price on Agilent Technologies from $57.00 to $65.00 and gave the company a “buy” rating in a research note on Wednesday, May 24th. Finally, Zacks Investment Research raised Agilent Technologies from a “hold” rating to a “buy” rating and set a $63.00 target price on the stock in a research note on Tuesday, May 16th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $63.18.
In other news, CFO Didier Hirsch sold 20,000 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $64.00, for a total transaction of $1,280,000.00. Following the completion of the transaction, the chief financial officer now directly owns 183,002 shares in the company, valued at approximately $11,712,128. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Boon Hwee Koh sold 4,500 shares of the stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $63.63, for a total transaction of $286,335.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 141,098 shares of company stock valued at $8,798,933.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.